AR087393A1 - ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY - Google Patents

ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY

Info

Publication number
AR087393A1
AR087393A1 ARP120102782A ARP120102782A AR087393A1 AR 087393 A1 AR087393 A1 AR 087393A1 AR P120102782 A ARP120102782 A AR P120102782A AR P120102782 A ARP120102782 A AR P120102782A AR 087393 A1 AR087393 A1 AR 087393A1
Authority
AR
Argentina
Prior art keywords
radiotherapy
cetuximab
ombrabulina
antitumoral combination
patients
Prior art date
Application number
ARP120102782A
Other languages
Spanish (es)
Inventor
Chantal Carrez
Celine Clemenson
Eric Deutsch
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR087393A1 publication Critical patent/AR087393A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Agente antitumoral destinado a pacientes tratados asimismo por radioterapia, que sufren especialmente cánceres y aún más particularmente atacados por tumores sólidos.Reivindicación 1: Combinación farmacéutica que comprende ombrabulina o AVE8062 en forma de base o en forma de una sal farmacéuticamente aceptable y cetuximab para su utilización como agente antitumoral destinado a pacientes tratados asimismo por radioterapia.Antitumor agent intended for patients also treated by radiotherapy, especially suffering from cancers and even more particularly attacked by solid tumors. Claim 1: Pharmaceutical combination comprising ombrabulin or AVE8062 as a base or in the form of a pharmaceutically acceptable salt and cetuximab for use as an antitumor agent for patients also treated by radiotherapy.

ARP120102782A 2011-08-01 2012-07-31 ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY AR087393A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1157044A FR2978663A1 (en) 2011-08-01 2011-08-01 ANTITUMOR COMBINATION COMPRISING OMBRABULIN AND CETUXIMAB ASSOCIATED WITH RADIOTHERAPY

Publications (1)

Publication Number Publication Date
AR087393A1 true AR087393A1 (en) 2014-03-19

Family

ID=46832547

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102782A AR087393A1 (en) 2011-08-01 2012-07-31 ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY

Country Status (5)

Country Link
AR (1) AR087393A1 (en)
FR (1) FR2978663A1 (en)
TW (1) TW201315461A (en)
UY (1) UY34233A (en)
WO (1) WO2013018018A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259598A (en) 1979-12-20 1981-03-31 General Electric Company Charge transfer signal processing apparatus transversal filter
CN1140272C (en) 1998-04-03 2004-03-03 味之素株式会社 Antitumor agents
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
PT1407784E (en) 2001-06-25 2011-03-03 Ajinomoto Kk Antitumor agents
FR2838437B1 (en) 2002-04-11 2004-06-04 Aventis Pharma Sa PROCESSES FOR THE PREPARATION OF COMBRETASTATINS
FR2895258B1 (en) 2005-12-22 2008-03-21 Aventis Pharma Sa COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2945210B1 (en) 2009-05-07 2011-07-01 Sanofi Aventis ANTITUMOR COMBINATION COMPRISING AVE8062 AND SORAFENIB

Also Published As

Publication number Publication date
FR2978663A1 (en) 2013-02-08
TW201315461A (en) 2013-04-16
WO2013018018A1 (en) 2013-02-07
UY34233A (en) 2013-02-28

Similar Documents

Publication Publication Date Title
PH12017550063A1 (en) Combination therapies for treating cancers
CL2015000699A1 (en) Methods for cancer treatment.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
WO2016025635A3 (en) Combination therapy for treating cancer
UY36307A (en) COMBINED THERAPIES FOR CANCER TREATMENT
CR20140108A (en) CYCLOPROPANOAMINE COMPOUND
MX2016007351A (en) Combination therapy for treating cancer.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX2019010601A (en) Combination therapy for treating cancer.
WO2015009726A3 (en) Medical uses of cd38 agonists
AU2011328009A8 (en) Compounds and methods for treating pain
MX2020012924A (en) Treatment of cancer using coenzyme q10 combination therapies.
ECSP13013060A (en) Therapeutic nuclease compositions and methods
MX2015014046A (en) Drug combinations to treat cancer.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2014003180A (en) Methods for treating hcv.
MX368903B (en) THERAPEUTIC COMPOUNDS and USES THEREOF.
NI201500150A (en) CANCER TREATMENT WITH DIHYDROPIRAZINE-PIRAZINES × Provided in this method
WO2016043874A3 (en) Combination therapy for treating cancer
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
MX2015014599A (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer.
MX2014010713A (en) Procaspase 3 activation by combination therapy.
CL2017000050A1 (en) Combination Therapy for Cancer
CL2013003324A1 (en) Composition comprising chemotherapy with paclitaxel and carboplatin and an anti-clusterine oligonucleotide; use of the composition for the treatment of a human patient suffering from lung cancer.
ECSP14013195A (en) CATHETER, IN PARTICULAR PERMANENT CATHETER FOR THE TREATMENT OF DYSFUNCTIONS AND / OR DISEASES OF THE BLADDER AND / OR THE PROSTATE.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal